紫杉醇联合顺铂在治疗晚期食道癌患者的临床应用疗效研究.docVIP

紫杉醇联合顺铂在治疗晚期食道癌患者的临床应用疗效研究.doc

  1. 1、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。。
  2. 2、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载
  3. 3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
  4. 4、该文档为VIP文档,如果想要下载,成为VIP会员后,下载免费。
  5. 5、成为VIP后,下载本文档将扣除1次下载权益。下载后,不支持退款、换文档。如有疑问请联系我们
  6. 6、成为VIP后,您将拥有八大权益,权益包括:VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
  7. 7、VIP文档为合作方或网友上传,每下载1次, 网站将根据用户上传文档的质量评分、类型等,对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档
查看更多
紫杉醇联合顺铂在治疗晚期食道癌患者的临床应用疗效研究.doc

紫杉醇联合顺铂在治疗晚期食道癌患者的临床应用疗效研究   [摘要] 目的 研究和探讨紫杉醇和顺铂在治疗晚期食道癌中的临床效果。方法 选取2011年2月―2014年1月该院收治的123例处于晚期的食道癌患者作为研究对象,按照化疗的方案不同分成观察组(51例)和对照组(72例)。观察组患者给予紫杉醇加顺铂的治疗,对照组患者给予5氟尿嘧啶加顺铂进行治疗。分析对比两组所收的治疗效果。 结果 观察组和对照组患者的有效率分别为54.91%和48.61%,两组总有效率对比,其差异无统计学意义(χ2=0.335,P0.05);经过6~45个月随访,观察组患者的TTP与MST值分别为(6.6±1.4)、(10.3±2.1)月,明显高于对照组患者,两组患者的TTP与MST值对比,差异有统计学意义(P0.05)。 结论 对于晚期食道癌患者,采用紫杉醇联合顺铂进行治疗,疗效显著,而且能明显延缓肿瘤进展的时间,并延长癌症患者的生存期,因此,可以在临床治疗中大力推广。   [关键词] 食道癌;顺铂;紫杉醇;化疗放疗   [中图分类号] R735.7 [文献标识码] A [文章编号] 1674-0742(2015)02(b)-0012-02   Clinical Application Efficacy of Paclitaxel Combined with Cisplatin in the Treatment of Advanced Esophageal Cancer   SONG Huali   Digestive Tumor Center, 263 Hospital of PLA, Beijing, 101149 China   [Abstract] Objective To study and investigate the clinical effect of Paclitaxel combined with Cisplatin in the treatment of advanced esophageal cancer. Methods 123 patients with advanced esophageal cancer admitted to our hospital from 2011 February to 2014 January were selected as the subjects and divided into the observation group(51 cases) and the control group(72 cases) in accordance with the chemotherapy regimen. Patients in the observation group were treated by Paclitaxel combined with Cisplatin, while those in the control group were treated by 5-Fluorouracil combined with Cisplatin. And the therapeutic effects of the two groups were analyzed and compared. Results The response rate of the observation group and the control group was 54.91% and 48.61%, respectively, the difference between the two groups was not statistically significant (x2=0.335, P0.05). The result of 6-45 months follow-up showed that the value of TTP and MST of the observation group was (6.6±1.4) months,(10.3±2.1) months, respectively, much longer than that of the control group, respectively, the differences between the two groups were statistically significant(P0.05). Conclusion For patients with advanced esophageal cancer, Paclitaxel combined with Cisplatin has remarkable curative

文档评论(0)

ganpeid + 关注
实名认证
文档贡献者

该用户很懒,什么也没介绍

1亿VIP精品文档

相关文档